Kevin Courtney, M.D., Ph.D.

Dr. Courtney is originally from New Hampshire. He initially was drawn to cancer research as an undergraduate at Dartmouth College, where he studied chromium carcinogenesis in the laboratory of Dr. Karen Wetterhahn. He received his M.D. and his Ph.D. in molecular cancer biology from Duke University through the Medical Scientist Training Program. After completing his residency training in Internal Medicine at the University of California, San Francisco, Dr. Courtney returned to the East Coast for his hematology/oncology fellowship at the Dana-Farber Cancer Institute. There he pursued post-doctoral studies in signal transduction in the laboratory of Dr. Lewis Cantley. Following his fellowship, Dr. Courtney continued on as an Instructor in Medicine at Harvard Medical School and an attending oncologist at Dana-Farber in the Lank Center for Genitourinary Oncology. Dr. Courtney joined the faculty at UT Southwestern in 2012. He specializes in genitourinary malignancies, with an emphasis on prostate and kidney cancer. Dr. Courtney's research efforts are focused on developing investigator-initiated clinical trials in prostate and kidney cancer that draw on his background in laboratory research and the outstanding basic science currently being carried out at UTSW. Dr. Courtney enjoys spending time with his family outdoors in the warm Dallas weather.

Graduate School	Duke University (2001)
Medical School	Duke University (2002)
Residency	University of California San Francisco (2005), Internal Medicine
Fellowship	Dana-Farber Cancer Institute (2008), Oncology

• Cancer
• Urologic Cancer

• Primary Interests
• Kidney Cancer, Masses & Tumors
• Oncology Clinical Trials
• Oncology Developmental Therapeutics (New or Latest Cancer Treatments)
• Prostate Cancer

• Clinical-translational research in genitourinary oncology
• Industry- and cooperative group-sponsored trials in genitourinary malignancies
• Investigator-initiated clinical trials in kidney cancer
• Investigator-initiated clinical trials in prostate cancer
• Novel biomarkers and therapeutics in prostate and kidney cancer

Featured Publications

The PI3K pathway as drug target in human cancer

Courtney KD, Corcoran RB, Engelman JA Journal of Clinical Oncology 2010 28 1075-83

Optimizing recent advances in metastatic renal cell carcinoma

Courtney KD, Choueiri TK Current Oncology Reports 2009 11 218-226

The Abl interactor proteins localized to sites of actin polymerization at the tips of lamellipodia and filopodia

Stradal T, Courtney KD, Rottner K, Hahne P, Small JV, Pendergast AM Current Biology 2001 11 891-5

Localization and phosphorylation of Abl-interactor proteins, Abi-1 and Abi-2, in the developing nervous system

Courtney KD, Grove M, Vandongen H, Vandongen A, LaMantia A-S, Pendergast AM Molecular and Cellular Neuroscience 2000 16 244-57

Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway

Dai Z, Quackenbush RC, Courtney KD, Grove M, Cortez D, Reuther GW, Pendergast AM Genes and Development 1998 12 1415-24

Featured Books

PI3K. In Molecular Oncology: Causes of Cancer and Targets for Treatment

Courtney KD, Cantley LC (2012).

• Career Development Award
  Genentech, Inc. Dana-Farber/Partners Cancer Center (2008)
• Young Investigator Award
  American Society of Clinical Oncology (2008)
• Sigma Xi
  Member (1993)
• Phi Beta Kappa
  Membership (1992)

• American Association of Cancer Research (2009)
• American Society of Clinical Oncology (2008)
• American Society of Clinical Oncology (2007-2008)